FIELD: biotechnology.
SUBSTANCE: humanised monoclonal antibody (MAb) specific to syndecan-1 (CD138) is proposed, which is characterised by amino acid and nucleotide sequences. According to the present invention, the antibody belongs to isotype IgG4 kappa, at that the constant fragments are fully human and modified by administration of sites IgG3 imparting to antibody the independent antibody-dependent and complement-dependent cytotoxicity, and amino acid substitutions that enable to increase the antibody gun. The variable sites are presented by murine hypervariable and human framework sites, providing an increase in binding affinity with a ligand. Each chain additionally comprises a signal secretory sequence at the N-terminus cleaved upon secretion from the producing cells. The nucleotide sequences are optimised to enhance antibody production in mammalian cells. The present invention may find additional application in the treatment of diseases associated with CD138, including malignant tumours (cancer).
EFFECT: increased efficiency of use of the compounds.
2 cl, 2 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2015 |
|
RU2611685C2 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC FOR LEGUMAIN | 2013 |
|
RU2574203C2 |
| ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY | 2014 |
|
RU2679715C1 |
| CD138-TARGETED CELL AGENTS AND USING THEM | 2008 |
|
RU2537265C2 |
| ANALGETIC AGENT ON THE BASIS OF PLASMID DNA CODING HNP-1, OR HNP-2, OR HNP-3 (VERSIONS) | 2014 |
|
RU2597789C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| ANTI-CD138 IMMUNOCONJUGATES AND USING THEM | 2008 |
|
RU2547939C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2006 |
|
RU2494107C2 |
